Presentation is loading. Please wait.

Presentation is loading. Please wait.

Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation  Thomas Bärnthaler, MD, Katharina Jandl, PhD, Heinz Sill,

Published byΒαυκις Μανωλάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation  Thomas Bärnthaler, MD, Katharina Jandl, PhD, Heinz Sill,"— Presentation transcript:

1 Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation 
Thomas Bärnthaler, MD, Katharina Jandl, PhD, Heinz Sill, MD, Barbara Uhl, MD, Yannick Schreiber, BSc, Magdalena Grill, PhD, Dominique Thomas, PhD, Rudolf Schicho, PhD, Gunther Marsche, PhD, Saša Frank, PhD, Akos Heinemann, MD, Rufina Schuligoi, PhD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 2, Pages e10 (February 2019) DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions

2 Fig 1 Imatinib concentration- and time-dependently promotes PGE2 biosynthesis via thromboxane synthase inhibition and abrogates LPS-induced TNF-α release through EP4 receptor–mediated NF-κB inhibition. (A-H) Monocytes or (I) U937T cells, containing NF-κB–GFP reporter cassette, were treated with vehicle (veh) or imatinib before cells were stimulated with LPS. A-C, Imatinib was added at the indicated concentrations and cells incubated for 20 hours. D-F, Timecourse experiments with imatinib (1 μM). G-I, Cells were pretreated with vehicle, diclofenac (diclo; 1 μM), or the EP4 antagonist ONO AE3-208 (0.3 μM) and incubated for 20 hours. A-H, N = 6 to 11; I, N = 3 to 6; values were calculated as percent of LPS stimulation alone, and are shown as mean + SEM. A-C, G, and H, Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test; (D-F) with 2-way ANOVA for repeated measurements followed by Sidak multiple comparison test; and (I) with 1-way ANOVA for repeated measurements followed by Tukey multiple comparison test. *P < .05, **P < .01, and ***P < .001 as compared with vehicle, #P < .05 and ##P < .01 as compared with imatinib alone. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

3 Fig 2 Patients treated with imatinib show increased biosynthesis of PGs but a decrease in TXB2 and proinflammatory cytokine release. Whole-blood samples from patients receiving imatinib and matched controls were treated with (A) vehicle or (B and C) LPS (10 μg/mL) for 4 hours. (Fig 2, A and B) Prostanoids and (Fig 2, C) cytokines were determined in plasma. Values are shown as mean + SEM of n = 19 independent experiments. Statistical analysis was performed with Mann-Whitney test. *P < .05, **P < .01, and ***P < .001. In D and E, the levels of TXB2 and PGE2, expressed as % of total prostanoid content, were correlated with each other using linear regression analysis and panel F shows the respective proportions. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

4 Fig E1 Patient blood cell counts show no considerable deviation from the values obtained in healthy humans. (A) Differential blood cell count and (B) blood cell count in patients were performed at the time of the experiments shown in Fig E2. Red bars indicate the reference range of the laboratory, while green error bars mark the 95% CI of the values obtained from patients (n = 19). Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

5 Fig E2 The inhibition of LPS-induced TNF-α release in monocytes by imatinib is not affected by EP1, EP2, or EP3 receptor antagonism. Monocytes were pretreated with the EP1 antagonist ONO8711 (1 μM), the EP2 antagonist PF (1 μM), or the EP1, EP2, and EP3 antagonist AH6809 (10 μM) 20 minutes before addition of imatinib (1 μΜ) followed by addition of LPS (10 ng/mL) and incubation for another 20 hours. Thereafter, the concentrations of (A) TNF-α and (B) PGE2 were determined in the supernatants. All experiments were done in duplicate. Values were calculated as percent of LPS stimulation alone, and are shown as mean + SEM of 6 independent experiments. Statistical analysis was performed with 1-way ANOVA followed by Tukey multiple comparison test. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

6 Fig E3 The inhibition of TNF-α release by imatinib and nilotinib depends on PGE2 release and EP4 receptor activation in monocyte-derived macrophages. Cells were pretreated with diclofenac (diclo, 1 μΜ) or the EP4 antagonist ONO AE3-208 (0.3 μM), 20 minutes before addition of imatinib (1 μΜ) or nilotinib (0.05 μM), followed by addition of LPS (10 ng/mL) and incubation for another 20 hours. Thereafter, the concentrations of (A) TNF-α and (B) PGE2 were determined in the supernatants. All experiments were done in duplicate. Values were calculated as percent of LPS stimulation alone, and are shown as mean + SEM of 6 independent experiments. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Tukey multiple comparison test. *P < .05, **P < .01, and ***P < .001 as compared with LPS stitmulation. #P < .05 as compared with imatinib or nilotinib treatment alone. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

7 Fig E4 Imatinib and nilotinib concentration-dependently increase PGE2 and inhibit TXB2 in human whole blood; the inhibition of TNF-α release depends on PGE2 release and EP4 receptor activation. Whole blood was treated with vehicle (veh) or with (A and C) imatinib or (B and D) nilotinib at the indicated concentrations 20 minutes before stimulation with LPS (10 μg/mL) for 4 hours. In E and F, whole blood was treated with diclofenac (diclo, 1 μM) or the EP4 antagonist ONO AE3-208 (0.3 μM), 20 minutes before addition of imatinib or nilotinib at the indicated concentrations, followed 20 minutes later by addition of LPS (10 μg/mL) and incubation for 4 hours. Thereafter, the concentrations of (Fig E4, A, B, and F) PGE2, (Fig E4, C, D, and E), TNF-α, and (G and H) TXB2 were determined in plasma. Values are calculated as percent of vehicle (LPS treatment) and shown as mean + SEM of 8 to 9 independent experiments. ND, Not detectable. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test; *P < .05, **P < .01, and ***P < .001 as compared with vehicle stimulation. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

8 Fig E5 Nilotinib concentration- and time-dependently promotes PGE2 biosynthesis via thromboxane synthase inhibition and abrogates LPS-induced TNF-α release through PGE2 and EP4 receptor activation. A-C, Monocytes were pretreated with vehicle (veh) or nilotinib with the indicated concentrations, before cells were stimulated with LPS (10 ng/mL) for 20 hours. D and E, In timecourse experiments, monocytes were treated with vehicle or nilotinib (0.05 μM) before stimulation with LPS and incubated for the indicated time points. G and H, Monocytes were pretreated with vehicle, diclofenac (diclo, 1 μM), or the EP4 antagonist ONO AE3-208 (0.3 μM) before addition of nilotinib, followed by addition of LPS (10 ng/mL) for another 20 hours. (Fig E5, A, D, and G) TNF-α, (Fig E5, B, E, and H) PGE2, and (Fig E5, C and F) TXB2 were determined in the supernatants. N = 6 to 11; values were calculated as percent of LPS stimulation alone, and are shown as mean + SEM. A-C, G, and H, Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test. *P < .05, **P < .01, ***P < .001. D-F, Timecourse experiments were analyzed by 2-way ANOVA for repeated measurements followed by Sidak multiple comparison test. *P < .05, **P < .01, ***P < .001. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

9 Fig E6 Inhibition of kinases has no direct effect on imatinib- and nilotinib-induced PGE2 release and the inhibition of LPS-induced TNF-α release. A and B, Adherent monocytes were pretreated with vehicle (veh), the p38MAPK inhibitor SB (p38), the MEK1/2 inhibitor PD (MEK1/2), the JNK inhibitor SP (JNK), and the PI3K inhibitor LY (PI3K), 20 minutes before addition of imatinib (1 μM) or nilotinib (0.05 μM) followed by addition of LPS (10 ng/mL) and incubation for 20 hours. C, To test whether the abrogation of the inhibitory effect of imatinib by PI3K and MEK1/2 inhibition was due to inhibition of PGE2 release, cells were pretrated with LY and PD as described for (Fig E6, A and B) and PGE2 (10 ng/mL) was added 20 minutes before stimulation with LPS. Thereafter, the concentrations of (Fig E6, A) PGE2 and (Fig E6, B and C) TNF-α were determined in the supernatants. All experiments were done in duplicate. Values are calculated as ng/mL, and shown as mean + SEM of 5 to 8 independent experiments. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test for comparison to vehicle treatment; *P < .05, **P < .01, and ***P < .001 as compared with the respective vehicle treatment (without imatinib or nilotinib); #P < .05 and ###P < .001 as compared with vehicle without inhibitors. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

10 Fig E7 Imatinib and nilotinib inhibit arachidonic acid (AA) and PGH2 induced TXB2 release in washed platelets and platelet microsomes, but have no effect on aggregation. Washed platelets or platelet microsomes were pretreated with vehicle (veh), imatinib (imat; 1 μM), nilotinib (nilo; 0.05 μM), or furegrelate (furegrelat; indicated concentrations, or in case of microsomes 0.3 μM) for 10 minutes. Thereafter, platelets or microsomes were stimulated with (A and B) AA (10 μM) or (C-E) PGH2 (12 μM) and (Fig E7, B and D) aggregation was measured as described in the Methods section. (Fig E7, A and C) TXB2 was determined in the platelet suspension at the end of the aggregation experiment (Fig E7, E) and in the microsome suspension. F and G, Representative recordings of aggregation. Data are shown (Fig E7, A and C) as % of vehicle, (Fig E7, E) as ng/μg protein/min, or (Fig E7, B and D) as percent of induced aggregation as mean + SEM of 6 to 9 independent experiments. Statistical analysis was performed with 1-way ANOVA for repeated measurements followed by Dunnett test for comparison with vehicle. *P < .05, **P < .01, ***P < .001. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

Download ppt "Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation  Thomas Bärnthaler, MD, Katharina Jandl, PhD, Heinz Sill,"

Similar presentations

Proinflammatory cytokine–induced and chemical mediator–induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein.

Proinflammatory cytokine–induced and chemical mediator–induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein.
Leukotriene B4 Inhibits L-Type Calcium Channels via p38 Signaling Pathway in Vascular Smooth Muscle Cells Cell Physiol Biochem 2015;37:1903-1913.

Leukotriene B4 Inhibits L-Type Calcium Channels via p38 Signaling Pathway in Vascular Smooth Muscle Cells Cell Physiol Biochem 2015;37:
The importance of being “pure” neutrophils

The importance of being “pure” neutrophils
Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites 

Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites 
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody  Seung Y. Chu, PhD, Holly M. Horton, PhD,

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody  Seung Y. Chu, PhD, Holly M. Horton, PhD,
Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic.

Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic.
Modulation by aspirin of nuclear phospho–signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated.

Modulation by aspirin of nuclear phospho–signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated.
Akos Heinemann, MD, Gunter J. Sturm, MD, Martina Ofner, BSc, Eva M

Akos Heinemann, MD, Gunter J. Sturm, MD, Martina Ofner, BSc, Eva M
IgE cross-linking impairs monocyte antiviral responses and inhibits influenza-driven TH1 differentiation  Regina K. Rowe, MD, PhD, David M. Pyle, MD,

IgE cross-linking impairs monocyte antiviral responses and inhibits influenza-driven TH1 differentiation  Regina K. Rowe, MD, PhD, David M. Pyle, MD,
Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm,

Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm,
Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes  Naoko Kanda, MD, PhD, Hiroshi Mitsui, MD, PhD, Shinichi.

Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes  Naoko Kanda, MD, PhD, Hiroshi Mitsui, MD, PhD, Shinichi.
IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-α expression in monocytes: Implications for chronic obstructive pulmonary disease 

IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-α expression in monocytes: Implications for chronic obstructive pulmonary disease 
Histamine H2 receptor stimulation upregulates TH2 chemokine CCL17 production in human M2a macrophages  Susanne Mommert, PhD, Karl Gregor, MD, Kristine.

Histamine H2 receptor stimulation upregulates TH2 chemokine CCL17 production in human M2a macrophages  Susanne Mommert, PhD, Karl Gregor, MD, Kristine.
TNF-α/IL-17 synergy inhibits IL-13 bioactivity via IL-13Rα2 induction

TNF-α/IL-17 synergy inhibits IL-13 bioactivity via IL-13Rα2 induction
Ramses Ilarraza, PhD, Yingqi Wu, Christopher D

Ramses Ilarraza, PhD, Yingqi Wu, Christopher D
FcεRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells  Shigeru Okumura, DDS, PhD, Hironori Sagara,

FcεRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells  Shigeru Okumura, DDS, PhD, Hironori Sagara,
Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent.

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent.
Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic.

Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic.
Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma  Malgorzata Pierzchalska,

Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma  Malgorzata Pierzchalska,
Evidence of a role for B cell–activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps  Atsushi Kato, PhD,

Evidence of a role for B cell–activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps  Atsushi Kato, PhD,

Similar presentations

Ads by Google